Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia - Comparison with historic experience

Cancer

Volumn 103, Issue 10, 2005, Pages 2099-2108

  Kantarjian, Hagop ^a   Talpaz, Moshe ^a   O'Brien, Susan ^a   Giles, Francis ^a   Faderl, Stefan ^a   Verstovsek, Srdan ^a   Garcia Manero, Guillermo ^a   Shan, Jianqin ^a   Rios, Mary Beth ^a   Champlin, Richard ^a   De Lima, Marcos ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Accelerated phase; Chronic myelogenous leukemia; Imatinib mesylate; Survival

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE; IMATINIB;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EXPERIENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ANEMIA; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; COHORT STUDIES; CYTOGENETIC ANALYSIS; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HEMOGLOBINS; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 18044371828     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21032     Document Type: Review

References (31)

1. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia: current status and investigational options. Science. 1990;274:824-830.
2. Kelliher M, McLaughlin J, Witte O, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and bcr/abl. Proc Natl Acad Sci USA. 1990;87:6649-6653.
3. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
4. Goldman JM, Melo JF. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1461-1464.
5. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988:61:1441-1446.
6. Savage DG, Sazydlo RM, Chase A, Apperley JF, Goldman JM. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol. 1997;99:30-35.
7. Vardiman J, Harris N, Brunning R. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
8. Druker B, Tamura S, Buchduner E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
9. Druker BJ. Update on imatinib therapy for chronic myeloid leukemia. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology, 6th edition. Volume 16. Philadelphia: Lippincott Williams & Wilkins, 2002:1-10.
10. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of specific inhibitor of the BCR-ABL tyrosine in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
11. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
12. Kantarjian H, Sawyers CL, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
13. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study. Blood. 2002;99:1928-1937.
14. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood. 2002;99:3530-3539.
15. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
16. Kantarjian H, O'Brien S, Cortes J, et al. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-α regimens for early chronic phase. Cancer. 2003;98:1430-1437.
17. Kantarjian H, O'Brien S, Cortes J, et al. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-α failure and in late CML-CP, comparison with historical controls. Clin Cancer Res. 2004;10:68-75.
18. Kantarjian HM, O'Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer. 2003;98:2636-2642.
19. Kantarjian HM, O'Brien S, Cortes JE, et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002;8:2167-2176.
20. Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003;9:160-166.
21. Hochhaus A, Reiter A, Saussele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood. 2000;95:62-66.
22. Paschka P, Muller M, Merx K, et al. Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon-alpha. Low levels of residual disease are associated with continuous remission. Leukemia. 2003;17:1687-1694.
23. Hughes T, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
26. Cox DR. Regression models and life tables (with discussion). J R Stat Soc. 1972;34:187-220.
27. Cortes J, Talpaz M, O'Brien S, et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003;98:1105-1113.
28. Huntly B, Guilhot F, Reid A, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood. 2003;102:2205-2212.
29. Marin D, Marktel S, Bua M, et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia. 2003;17:1448-1453.
30. National Marrow Donor Program. Disease and transplant outcome data, NMDP-facilitated transplant outcomes. National Marrow Donor Program, 2004. Available from URL: http://www.marrow.org/MEDICAL/disease outcome data.html [accessed September 15, 2004].
31. Shah N, Tran C, Lee F, Chen P, Norris D, Sawyers C. Over-riding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401.